{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=76",
    "query": {
      "intervention": "Placebo Comparator A",
      "page": 76
    },
    "page_size": 10
  },
  "pagination": {
    "page": 76,
    "page_size": 10,
    "total_count": 27155,
    "total_pages": 2716,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=77&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+A&page=75&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T20:26:38.768Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05265910",
      "title": "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "olopatadine hydrochloride ophthalmic solution 0.7%",
          "type": "DRUG"
        },
        {
          "name": "loratadine 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Tears Naturale",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andover Research Eye Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-12-14",
      "completion_date": "2022-04-23",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05265910"
    },
    {
      "nct_id": "NCT00977938",
      "title": "The Dual Antiplatelet Therapy Study (DAPT Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Placebo & Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel & Aspirin, Prasugrel & Aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baim Institute for Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25682,
      "start_date": "2009-10",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-09",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 178,
      "location_summary": "Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977938"
    },
    {
      "nct_id": "NCT00184548",
      "title": "Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Trauma"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 554,
      "start_date": "2005-10",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-06-25",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00184548"
    },
    {
      "nct_id": "NCT00611026",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Tolterodine ER",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fesoterodine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2417,
      "start_date": "2008-02",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2011-02-02",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 102,
      "location_summary": "Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more",
      "locations": [
        {
          "city": "Enterprise",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611026"
    },
    {
      "nct_id": "NCT01207115",
      "title": "A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "ABT-652",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 322,
      "start_date": "2010-09",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-01-07",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 23,
      "location_summary": "Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 20 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01207115"
    },
    {
      "nct_id": "NCT00103935",
      "title": "Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Exenatide LAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2005-02",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2015-02-24",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 7,
      "location_summary": "Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Butte",
          "state": "Montana"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103935"
    },
    {
      "nct_id": "NCT04988308",
      "title": "A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Bermekimab",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2021-10-12",
      "completion_date": "2022-11-23",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Fremont, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04988308"
    },
    {
      "nct_id": "NCT01467076",
      "title": "Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prematurity",
        "Respiratory Insufficiency",
        "Pulmonary Hypertension",
        "Respiratory Distress Syndrome, Newborn"
      ],
      "interventions": [
        {
          "name": "Aerosolized Normal Saline",
          "type": "DRUG"
        },
        {
          "name": "Inhaled PGE1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "7 Days",
        "sex": "ALL",
        "summary": "Up to 7 Days"
      },
      "enrollment_count": 7,
      "start_date": "2011-11",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01467076"
    },
    {
      "nct_id": "NCT00651417",
      "title": "Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Localized Breast Cancer",
        "Localized Prostate Cancer",
        "Patients Receiving External Beam Radiotherapy"
      ],
      "interventions": [
        {
          "name": "Organic Germanium",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Arizona Oncology Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2005-04",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2011-06-23",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651417"
    },
    {
      "nct_id": "NCT04781140",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "48 Months",
        "maximum_age": "69 Months",
        "sex": "ALL",
        "summary": "48 Months to 69 Months"
      },
      "enrollment_count": 286,
      "start_date": "2024-03-19",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-22T20:26:38.768Z",
      "location_count": 54,
      "location_summary": "Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04781140"
    }
  ]
}